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Abstract
We evaluated deguelin and silibinin in A/J mice treated
with the tobacco-specific carcinogen benzo(a)pyrene
(BP) for their ability to inhibit pulmonary adenoma for-
mation and growth. Animals were treated with either
deguelin (5.0 or 10.0 mg/kg body weight, by gavage) or
silibinin at doses of 0.05% and 0.1% in the diet, approxi-
mately 10 days before a single intraperitoneal dose of
BP. We found that oral administration of deguelin re-
duced tumor multiplicity by 56% and tumor load by
78%, whereas silibinin treatment at doses of 0.05%
and 0.1% in the diet did not show any significant effi-
cacy on either tumormultiplicity or tumor load. The result
indicates that deguelin significantly inhibits pulmonary
adenoma formation and growth in A/J mice. Finding new
and effective agents that can prevent lung cancer is
urgently needed because cancer of the lungs remains the
principal cause of cancer deaths in the United States and
because effective chemoprevention of this cancer type
remains elusive. Thus, deguelin appears to be a promis-
ing new preventive agent for lung cancer and may be
considered for further studies in other animalmodels and
in clinical trials.
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Introduction
Lung cancer is the leading cause of cancer deaths in men
and women in the United States and western Europe [1].
Epidemiological and laboratory animal model studies have
demonstrated that smoking and environmental exposure
to carcinogens are closely linked to increased lung cancer
risk [2–5]. Tobacco exposure has been implicated in 90%
of lung carcinomas, and smokers have a 20-fold greater risk
of developing lung cancer compared with persons who have
never smoked [6–9]. Chemoprevention is a potentially im-
portant approach to reduce the large number of tobacco-
caused cancer deaths in both current and former smokers.
Chemoprevention is the use of pharmacological or natural
agents to inhibit the development of cancer. Numerous
studies have found that chemoprevention can prevent a
wide variety of cancers in multiple animal models [10]. This
approach is especially useful in targeting persons who are at
high risk for developing cancer, such as those who are at high
risk for developing a second primary tumor after surgical re-
moval of a tumor, those who have genotypes that put them at
high risk for specific forms of cancer, and those who have pre-
existing preinvasive lesions [10]. Targets for pharmacological
intervention are various stages of tumor development, includ-
ing hyperplasia and dysplasia. There are two major classes
of cancer chemopreventive agents: blocking agents and sup-
pressing agents [11–13]. Blocking agents prevent metabolic
activation of carcinogens to reduce the likelihood of DNA
damage or to enhance the repair of damaged DNA. Suppress-
ing agents block expansion of carcinogen-initiated cells by
suppressing cell replication, stimulating cell differentiation, or
causing apoptosis of precancerous or cancerous cells.
Because of similarities in histopathology and tumor progres-
sion stages between mouse and human lung adenocarcino-
mas, the mouse lung tumor model has been used extensively
to evaluate the efficacy of putative lung cancer chemopreven-
tive agents [3,14]. Among more than 50 different agents tested,
several groups of chemicals, including glucocorticoids and
isothiocyanates, have shown significant efficacy against
mouse lung tumor development. Glucocorticoids have proven
to be successful during the progression stage of tumor devel-
opment, whereas isothiocyanates have proven particularly
effective in blocking carcinogenesis [3,15]. The present inves-
tigation is a continuing effort to develop an effective chemo-
prevention of carcinogenesis of the lungs. There is a great
need for agents that can inhibit pulmonary neoplasia with
minimal or no toxicity and are effective during different periods
of the carcinogenic process. We evaluated two novel agents
(deguelin and silibinin) in A/J mice treated with the tobacco-
specific carcinogen benzo(a)pyrene (BP) for their ability to in-
hibit pulmonary adenoma formation and growth.
Deguelin is a rotenoid derived from plant roots [16].
Rotenone and rotenoid-containing botanicals are important
insecticides and fish poisons that act by inhibiting NADH:
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ubiquinone oxidoreductase, an enzyme complex present in
mitochondrial oxidative phosphorylation [16]. In addition and
potentially more relevant to cancer prevention, deguelin can
inhibit the PI3K/AKT pathway. Deguelin has shown chemo-
preventive efficacy in several in vivo and in vitro models
[17–20]. In an animal experimental in vivo system, deguelin
reduced tumor incidence in CD-1 mice skin carcinogenesis
[16] and tumor multiplicity of mammary tumorigenesis in
Sprague-Dawley rats [16]. In addition, treatment with deguelin
suppressed the formation of carcinogen-induced aberrant
crypt foci in the colon of CF-1 mice [17]. In several in vitro
experiments, deguelin has been reported to inhibit the
growth of colon cancer cells [20]. It could specifically inhibit
the growth of transformed human bronchial epithelial cells and
non–small cell lung cancer (NSCLC) cells [18,19].
Silibinin is a naturally occurring polyphenolic flavonoid.
Silymarin is composed of mainly silibinin (90%), with small
amounts of other silibinin stereoisomers. Several studies in
rodent and cell cultures have shown that silibinin is a strong
antioxidant that scavenges both free radicals and reactive
oxygen species, thereby providing significant protection
against different cancers of epithelial origin [21,22]. It has been
reported that silibinin inhibits the growth of advanced human
prostate carcinoma in nude mice [23] and of skin tumors in
SENCAR mice [24]. To date, there are no data on the chemo-
preventive efficacy of silibinin on lung tumorigenesis.
The goal of this investigation was to discover and develop
effective chemopreventive agents against lung tumorigenesis.
We determined the capacity of the two agents to prevent pul-
monary adenoma formation and growth, and we found that
deguelin is a potent inhibitor of lung tumorigenesis in A/J mice.
Materials and Methods
Reagents and Animals
BP, tricaprylin, and silibinin were purchased from Sigma
Chemical Co. (St. Louis, MO), whereas deguelin was pur-
chased from Gaia Chemical Corporation (Gaylordsville, CT).
Female A/J mice were obtained from Jackson Laboratories
(Bar Harbor, ME) at 6 weeks of age. Animals were quarantined
for 1 week and housed with wood chip bedding in environmen-
tally controlled, clean-air rooms with a 12-hour light–dark cycle
and a 50% relative humidity. Drinking water and diet were
supplied ad libitum. The study was approved by the Washing-
ton University’s Institutional Animal Care and Use Committee.
Animal Experiments
Mice were randomly divided into one control group and
two treatment groups. For deguelin testing, the groups con-
sisted of a control group and two groups of animals treated
with deguelin at 5.0 or 10.0 mg/kg body weight. Deguelin was
dissolved in corn oil just before administration and was
administered by gavage (intragastrically) 5 days/week for
the duration of the study. Control animals were treated with
corn oil (administered intragastrically) throughout the study.
For silibinin testing, the groups consisted of a control group
treated with AIN-76A purified pellet diet and two groups
treated with silibinin at 0.05% and 0.1% (wt/wt) doses mixed
with AIN-76A purified powder diet. Foods were prepared
once a week with a powerful KitchenAid mixer (St. Joseph,
MI) mixing for at least 1 hour. Treatments were initiated
10 days before carcinogen introduction. After 10 days of
treatment, all groups received a single intraperitoneal dose
of BP (100 mg/kg body weight) in 0.2 ml of tricaprylin. Body
weights of mice were measured every 2 weeks.
During the duration of the study, the health condition of
the mice was monitored everyday, and body weights were
measured every 2 weeks. Mice were sacrificed by CO2
asphyxiation 20 to 21 weeks after carcinogen treatment.
For the phenotyping of lung tumors in all bioassays described
above, lung tissues were fixed in Tellyesniczky’s solution
overnight, and then in 75% EtOH. Lung tumor development
was estimated by two investigators, using a Leica MZ75 dis-
sectingmicroscope, tomeasure the number (N ), volume (V ),
and total tumor load (NV ), as reported previously [25]. Vol-
ume calculation was based on the formula: V (mm3) = 4/3pr 3.
Histopathological examinations were performed to deter-
mine the diagnosis of lung tumors.
Statistical Analysis
We hypothesized that BP-induced lung tumors are more
likely to occur in the carcinogen control group than in the
treatment groups. To test this hypothesis, Student’s t test
was used. The datawere obtained from theBP control groups
and the different treatment groups in each experiment. We
applied square root transformation on tumor numbers be-
cause the original data did not follow normal distribution. The
transformed data were of normal distribution. Accordingly,
Student’s t test was used to test the differences between
the control groups and the treatment groups.
Results
Preventive agents can block tumor initiation either by blocking
carcinogen activation, by scavenging reactive carcinogens, or
potentially by enhancing DNA damage repair. In addition,
agents can suppress the progression of initiated cells. In this
study, we used the complete chemoprevention protocol, which
involves intervention at 1 to 2 weeks before carcinogen ad-
ministration. Preventive agents are used throughout the study.
This protocol is designed to determine both blocking and
suppressing effects on all stages of lung tumorigenesis (initi-
ation, promotion, and progression). Because the two com-
pounds are novel agents, deguelin and silibinin were tested
using this protocol based on the rationale that any agent that
was ineffective or minimally effective did not warrant further
consideration at the doses employed. The mice treated with
either deguelin or silibinin showed no signs of gross toxicity or
loss of body weight during the experiment (data not shown).
The administration of deguelin by gavage decreased tumor
multiplicity. The 5-mg/kg dose of deguelin decreased tumor
multiplicity from 7.15 ± 0.72 tumors per mouse (n = 15) in the
control group to 2.64 ± 0.45 tumors per mouse (n = 22, P <
.0001). The higher dose of 10mg/kg reduced tumormultiplicity
to 3.18 ± 0.44 tumors per mouse (n = 22,P < .0001) (Figure 1).
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Therefore, tumor multiplicity was reduced by 63% and 56%
in the 5- and 10-mg/kg groups, respectively (Figure 1). Deguelin
treatment showed substantial effects on tumor load: low-dose
treatment (5 mg/kg) reduced the tumor load by 57%, whereas
high-dose treatment (10mg/kg) inhibited the tumor load by 78%
(Figure 1). Finally, dietary feeding of silibinin at 0.05% and 0.1%
(wt/wt) doses to A/J mice with BP-induced lung tumorigenesis
did not show significant preventive efficacy (Figure 1). All of the
lung nodules found in this experiment were diagnosed as lung
adenomas (Figure 2).
Discussion
Effective chemoprevention of lung cancer—the principal
cause of cancer deaths in the United States—has not
been achieved. Characterization and use of effective chemo-
preventive agents have become important issues in the pre-
vention and control of this deadly disease, particularly in the
case of former smokers who are known to remain at high risk.
Aiming to identify novel chemopreventive agents for lung
cancer, we have determined the efficacy of two agents (de-
guelin and silibinin) in preventing lung tumorigenesis in mice.
We found that deguelin was an effective chemopreventive
agent in our mouse model of lung cancer at doses that caused
no significant toxicity. Both doses of 5 and 10 mg/kg deguelin
decreased tumor multiplicity by 63% and 56%, respectively
(both P < .0001; Figure 1). When examining tumor load, both
doses reduced tumor load in a dose-dependent manner
by 57% in the 5-mg/kg group (P < .05) and by 78% in the 10-
mg/kg group (P < .001) (Figure 1), respectively.
A systematic pharmacokinetic study of deguelin was
performed in rats [26]. Deguelin has a long mean residence
Figure 1. Effects of deguelin and silibinin on BP-induced lung tumorigenesis in A/J mice. (A) Experimental design. We used the complete protocol. The upper panel
shows the protocol for deguelin, and the lower panel shows the protocol for silibinin. After 10 days of administration of deguelin and silibinin, all mice were subjected
a single dose of BP (100 mg/kg body weight). The total treatment duration was 22 weeks. (B) Effect of deguelin on lung tumor multiplicity. Deguelin significantly
decreased tumor multiplicity by 63% and 56% in the 5- and 10-mg/kg groups, respectively. (C) Effect of deguelin on lung tumor load. Deguelin decreased tumor
load by 57% and 78% in a dose-dependent manner. (D) Effect of silibinin on lung tumor multiplicity. The treatment of silibinin did not show significant inhibitory
effects on tumor multiplicity in this entire study. (E) Effect of silibinin on lung tumor load. High-dose silibinin (0.1% in the diet) showed a mild (but not statistically
significant) inhibitory effect. Error bars indicate standard error. *P < .05, ***P < .001, and ****P < .0001, compared with the control group.
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time (6.98 hours) and half-life (9.26 hours) in rat plasma, with
reasonable levels distributed in the lungs. For example, the
relative levels of tissue distribution were as follows: perirenal
fat > heart > mammary gland > colon > kidney > liver > lung >
brain > skin, following intragastric administration [26]. De-
guelin has shown chemopreventive efficacy in several in vivo
models using dose levels similar to those of the present
study [17,26]. In a recent study, deguelin suppressed the
formation of carcinogen-induced aberrant crypt foci in the
colon of CF-1 mice when it was given intragastrically at
doses of 2.5, 5.0, and 10.0 mg/kg body weight [17]. The bio-
availability of silibinin in mouse models is well-documented
in the literature [23,27,28]. Oral feeding of silibinin at 200 mg/
kg resulted in physiologically available silibinin levels in both
lungs (20 mg/g lung tissue) and plasma (60 mM = 30 mg/ml)
[27]. Using 0.05% and 0.1% silibinin (wt/wt) in diets for
60 days, tumor volume was significantly decreased (35–
58%; P < .05–.001) in silibinin-fed mice [28]. We believe that
silibinin should be bioavailable in lung tissues because we
used identical doses of silibinin (0.05% and 0.1%, mixed in
AIN-76A purified powder diet) for more than 20 weeks, as
reported previously [28].
Recently, advances have been reported in the develop-
ment of small molecule inhibitors for Akt, which plays an
important role in cell survival and proliferation through a
number of downstream effectors. The majority of small mole-
cule inhibitors of Akt are adenosine triphosphate–competitive
inhibitors, phosphatidylinositol (PI) analogs, and allosteric
inhibitors with pleckstrin homology domain [29]. Deguelin, a
natural inhibitor of PI3K and AKT, can inhibit cell proliferation
by blocking cells in the G2/M phase of the cell cycle and by
increasing apoptosis in premalignant and malignant cells
[16–18]. One of the major mechanisms of action for the ob-
served chemopreventive efficacy of deguelin is through its
inhibitory effect on PI3K/Akt signaling [18]. Furthermore, the
PI3K signaling pathway has been reported to be involved in
the early stages of lung carcinogenesis [30,31]; increased
expression of activated Akt was observed in the early stages
of tobacco-induced lung carcinogenesis [18,30]. Deguelin was
previously shown to inhibit the formation of preneoplastic
lesions when mouse mammary glands were exposed to
7,12-dimethylbenz(a)anthracene (DMBA), skin carcinogens
in CD-1 mice, and MNU-induced mammary carcinogens in
Sprague-Dawley rats [16]. Deguelin was also effective in sup-
pressing the formation of carcinogen-induced aberrant crypt
foci by more than 70% in the colon of CF-1 mice, presumably
through the induction of apoptosis and cell cycle arrest [17,20].
The results from these studies and from the present study
clearly demonstrate that deguelin has a significant chemopre-
ventive efficacy against tumorigenesis in multiple organ sites.
Silibinin is a major bioactive flavanone in milk thistle and
has shown efficacy against tumor growth in prostate, skin,
and colon cancer models [27,32,33]. Recently, oral silibinin
was found to suppress human NSCLC A549 xenograft
growth and to enhance therapeutic response to doxorubicin
in athymic mice, suggesting that silibinin may be a poten-
tial chemopreventive agent for lung tumorigenesis [26]. How-
ever, administration of silibinin in the diet did not reduce lung
tumor multiplicity or tumor load, indicating that silibinin has
no significant efficacy at the doses employed in BP-induced
mouse lung tumorigenesis. At present, it is not clear why
silibinin failed to inhibit lung tumorigenesis as sufficient bio-
availability could be achieved with oral feeding of silibinin in
the in vivo setting [28].
In summary, the results of this study show that deguelin is
a novel lung chemopreventive agent in A/J mice. Identifica-
tion of new and effective agents against lung cancer is of
the highest importance because cancer of the lungs remains
the principal cause of cancer deaths and because effective
chemoprevention has not been found. For example, caro-
tene, retinol, and vitamins E and C have been shown to have
little, or negative, effect on human lung cancer development
in smokers [15]. Thus, deguelin is among the more promising
preventive agents for lung cancer and should be further
tested in clinical trials.
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